Precipio

PRPOPre-clinical

New Haven, United StatesFounded 2011precipiodx.com

Precipio is dedicated to transforming cancer diagnostics by addressing the critical issue of diagnostic error through its specialized laboratory services and proprietary technologies. The company has built a commercial laboratory operation offering a comprehensive menu of tests, including flow cytometry, cytogenetics, fluorescence in situ hybridization (FISH), and molecular diagnostics. Its strategic direction involves leveraging its expertise in complex diagnostics to capture market share in the underserved niche of accurate, rapid-turnaround cancer testing, while exploring the development of novel diagnostic platforms.

Market Cap

$48.8M

Founded

2011

Employees

50-100

Focus

Biotech

PRPO · Stock Price

USD 27.88+3.28 (+13.33%)

Historical price data

AI Company Overview

Technology Platform

Precipio operates an integrated diagnostic services platform, combining specialized pathology expertise with gold-standard technologies like flow cytometry, cytogenetics, and molecular diagnostics to deliver accurate, comprehensive cancer diagnostic reports.

Opportunities

Growth opportunities include expanding its referral network among community oncologists and hospitals, increasing test utilization per patient through its integrated menu, and potentially developing or acquiring proprietary diagnostic assays to enhance margins and differentiation.

Risk Factors

Key risks include ongoing financial losses and dependence on capital markets for funding, intense competition from larger diagnostic labs, reimbursement challenges from insurers, and the execution risk associated with scaling its commercial operations to achieve profitability.

Competitive Landscape

Precipio competes with large national labs (LabCorp, Quest, NeoGenomics) and academic medical centers. Its main differentiation is its focused service model on complex cancer diagnostics, combining subspecialist pathology expertise with integrated reporting from multiple technologies, positioning it as a high-touch alternative for difficult cases.